Publication
Publication list
Publication list
1. Lim H, Ma G, Jeong Y, Lee JH, Lee JH, Yang SB, Choi JU, Km HR*, Park J*. Tumor targeting in situ aggregation of nanoparticle-to-nanoparticle strategy to simultaneously induce ferroptosis and immunogenic cell death using complementary heparin and protamine molecules., Nano Today (IF:17.4, Materials science, multidisciplinary 5.4 %), 2024 Jun, 57: 102355. doi: 10.1016/j.nantod.2024.102355, *Corresponding authors
1. Lim H, Ma G, Jeong Y, Lee JH, Lee JH, Yang SB, Choi JU, Km HR*, Park J*. Tumor targeting in situ aggregation of nanoparticle-to-nanoparticle strategy to simultaneously induce ferroptosis and immunogenic cell death using complementary heparin and protamine molecules., Nano Today (IF:17.4, Materials science, multidisciplinary 5.4 %), 2024 Jun, 57: 102355. doi: 10.1016/j.nantod.2024.102355, *Corresponding authors
2. Kim HR*, Park SJ*, Cho YS, Choi JU, Park J, Kweon S, Lee NK, Knowledge M. Moyo, Chung SW, Ko YG, Yeo JH, Lee J, Kim SY, Byun Y. Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2024 Jun 20:372:176-193. doi: 10.1016/j.jconrel.2024.06.028. *First authors
2. Kim HR*, Park SJ*, Cho YS, Choi JU, Park J, Kweon S, Lee NK, Knowledge M. Moyo, Chung SW, Ko YG, Yeo JH, Lee J, Kim SY, Byun Y. Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2024 Jun 20:372:176-193. doi: 10.1016/j.jconrel.2024.06.028. *First authors
3. Kim HR*, Park SJ, Cho YS, Ko YG, Kim SY, Byun Y. Synergistic anticancer immunity in metastatic triple-negative breast cancer through an in situ amplifying Peptide-Drug Conjugate., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2024 ePub, *First author
3. Kim HR*, Park SJ, Cho YS, Ko YG, Kim SY, Byun Y. Synergistic anticancer immunity in metastatic triple-negative breast cancer through an in situ amplifying Peptide-Drug Conjugate., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2024 ePub, *First author
https://doi.org/10.1016/j.jconrel.2024.07.074
4. Cho YS*, Kim HR*, Park SJ, Chung SW, Ko YG, Yeo JH, Lee J, Kim SK, Choi JU, Kim SY, Byun Y. Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer, Biomaterials (IF: 15.304, Materials science, biomaterials 3.3 %), 2022 Oct; 289, 121783 *First authors
4. Cho YS*, Kim HR*, Park SJ, Chung SW, Ko YG, Yeo JH, Lee J, Kim SK, Choi JU, Kim SY, Byun Y. Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer, Biomaterials (IF: 15.304, Materials science, biomaterials 3.3 %), 2022 Oct; 289, 121783 *First authors
5. Kim HR*, Cho YS*, Chung SW, Choi JU, Ko YG, Park SJ, Kim SY, Byun Y. Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2022 Apr 22; 346:136-147. doi: 10.1016/j.jconrel.2022.04.014. *First authors
5. Kim HR*, Cho YS*, Chung SW, Choi JU, Ko YG, Park SJ, Kim SY, Byun Y. Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2022 Apr 22; 346:136-147. doi: 10.1016/j.jconrel.2022.04.014. *First authors
6. Park SJ, Kweon S, Knowledge M. Moyo, Kim HR, Park J, Choi JU, Kim BM, Park JW, Byun Y. Immune modulation of the liver metastatic colorectal cancer microenvironment via the oral CAPOX-mediated cGAS-STING pathway., Biomaterials (IF: 15.304, Materials science, biomaterials 3.3 %), 2024 Oct, 310:122625. doi: 10.1016/j.biomaterials.2024.122625
6. Park SJ, Kweon S, Knowledge M. Moyo, Kim HR, Park J, Choi JU, Kim BM, Park JW, Byun Y. Immune modulation of the liver metastatic colorectal cancer microenvironment via the oral CAPOX-mediated cGAS-STING pathway., Biomaterials (IF: 15.304, Materials science, biomaterials 3.3 %), 2024 Oct, 310:122625. doi: 10.1016/j.biomaterials.2024.122625
7. Cho YS*, Cho H*, Kim HR, Park SJ, Yeo JH, Ko YG, Lee J, Kim SY, Kim K, Byun Y. Bystander apoptosis enhanced systemic treatment of metastatic pancreatic cancer via macropinocytosis-targeted peptide-docetaxel conjugate therapy (Under revision), J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %)
7. Cho YS*, Cho H*, Kim HR, Park SJ, Yeo JH, Ko YG, Lee J, Kim SY, Kim K, Byun Y. Bystander apoptosis enhanced systemic treatment of metastatic pancreatic cancer via macropinocytosis-targeted peptide-docetaxel conjugate therapy (Under revision), J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %)
8. Cho YS, Kim GC, Lee HM, Kim B, Kim HR, Chung SW, Chang HW, Ko YG, Lee YS, Kim SW, Byun Y, Kim SY. Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2022 Apr; 344:26-38. doi: 10.1016/j.jconrel.2022.02.026.
8. Cho YS, Kim GC, Lee HM, Kim B, Kim HR, Chung SW, Chang HW, Ko YG, Lee YS, Kim SW, Byun Y, Kim SY. Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2022 Apr; 344:26-38. doi: 10.1016/j.jconrel.2022.02.026.
9. Lee NK, Choi JU, Kim HR, Chung SW, Ko YG, Cho YS, Park SJ, Lee EJ, Kim SY, Kim IS, Byun Y. Caspase-cleavable peptide-doxorubicin conjugate in combination with CD47-antagonizing nanocage therapeutics for immune-mediated elimination of colorectal cancer., Biomaterials (IF: 15.304, Materials science, biomaterials 3.3 %), 2021 Oct;277:121105. doi: 10.1016/j.biomaterials.2021.121105.
9. Lee NK, Choi JU, Kim HR, Chung SW, Ko YG, Cho YS, Park SJ, Lee EJ, Kim SY, Kim IS, Byun Y. Caspase-cleavable peptide-doxorubicin conjugate in combination with CD47-antagonizing nanocage therapeutics for immune-mediated elimination of colorectal cancer., Biomaterials (IF: 15.304, Materials science, biomaterials 3.3 %), 2021 Oct;277:121105. doi: 10.1016/j.biomaterials.2021.121105.
10. Choi JU, Kim JY, Chung SW, Lee NK, Park J, Kweon S, Cho YS, Kim HR, Lim SM, Park JW, Lee KC, Byun Y. Dual mechanistic TRAIL nanocarrier based on PEGylated heparin taurocholate and protamine which exerts both pro-apoptotic and anti-angiogenic effects., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8%), 2021 Aug 10;336:181-191. doi: 10.1016/j.jconrel.2021.06.019.
10. Choi JU, Kim JY, Chung SW, Lee NK, Park J, Kweon S, Cho YS, Kim HR, Lim SM, Park JW, Lee KC, Byun Y. Dual mechanistic TRAIL nanocarrier based on PEGylated heparin taurocholate and protamine which exerts both pro-apoptotic and anti-angiogenic effects., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8%), 2021 Aug 10;336:181-191. doi: 10.1016/j.jconrel.2021.06.019.
11. Cho YS, Chung SW, Kim HR, Won TH, Choi JU, Kim IS, Kim SY, Byun Y. The novel strategy for concurrent chemoradiotherapy by conjugating the apoptotic cell-binding moiety to caspase-3 activated doxorubicin prodrug., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2019 Feb 28;296:241-249. doi: 10.1016/j.jconrel.2019.01.020.
11. Cho YS, Chung SW, Kim HR, Won TH, Choi JU, Kim IS, Kim SY, Byun Y. The novel strategy for concurrent chemoradiotherapy by conjugating the apoptotic cell-binding moiety to caspase-3 activated doxorubicin prodrug., J Control Release (IF: 11.467, Pharmacology & Pharmacy 3.8 %), 2019 Feb 28;296:241-249. doi: 10.1016/j.jconrel.2019.01.020.
12. Chung SW, Cho YS, Choi JU, Kim HR, Won TH, Kim SY, Byun Y. Highly potent monomethyl auristatin E prodrug activated by caspase-3 for the chemoradiotherapy of triple-negative breast cancer. Biomaterials (IF: 15.304, Materials science, biomaterials 3.3 %), 2019 Feb;192:109-117. doi: 10.1016/j.biomaterials.2018.11.001.
12. Chung SW, Cho YS, Choi JU, Kim HR, Won TH, Kim SY, Byun Y. Highly potent monomethyl auristatin E prodrug activated by caspase-3 for the chemoradiotherapy of triple-negative breast cancer. Biomaterials (IF: 15.304, Materials science, biomaterials 3.3 %), 2019 Feb;192:109-117. doi: 10.1016/j.biomaterials.2018.11.001.
13. Chung SW, Choi JU, Cho YS, Kim HR, Won TH, Dimitrion P, Jeon OC, Kim SW, Kim IS, Kim SY, Byun Y. Self-Triggered Apoptosis Enzyme Prodrug Therapy (STAEPT): Enhancing Targeted Therapies via Recurrent Bystander Killing Effect by Exploiting Caspase-Cleavable Linker. Adv Sci (Weinh) (IF: 17.521, Materials science, multidisciplinary 6.8 %), 2018 Jun 5;5(7):1800368. doi: 10.1002/advs.201800368.
13. Chung SW, Choi JU, Cho YS, Kim HR, Won TH, Dimitrion P, Jeon OC, Kim SW, Kim IS, Kim SY, Byun Y. Self-Triggered Apoptosis Enzyme Prodrug Therapy (STAEPT): Enhancing Targeted Therapies via Recurrent Bystander Killing Effect by Exploiting Caspase-Cleavable Linker. Adv Sci (Weinh) (IF: 17.521, Materials science, multidisciplinary 6.8 %), 2018 Jun 5;5(7):1800368. doi: 10.1002/advs.201800368.
14. Kim HR*, Park JH, Park SJ, Park J, Choi JU, Kweon S, Lee NK, Ko YG, Cho YS, Kim SY, Byun Y. A novel gemcitabine prodrug with albumin binding property for KRAS mutant pancreatic cancer targeting., (In preparation)
14. Kim HR*, Park JH, Park SJ, Park J, Choi JU, Kweon S, Lee NK, Ko YG, Cho YS, Kim SY, Byun Y. A novel gemcitabine prodrug with albumin binding property for KRAS mutant pancreatic cancer targeting., (In preparation)
15. Kim HR*, Lim G*, Lee DY, Targeted anti-inflammatory treatment of inflammatory bowel disease using mucoadhesive chitosan oligosaccharide-glycyrrhizin nanoparticles, (In preparation)
15. Kim HR*, Lim G*, Lee DY, Targeted anti-inflammatory treatment of inflammatory bowel disease using mucoadhesive chitosan oligosaccharide-glycyrrhizin nanoparticles, (In preparation)
16. Park SJ*, Kim HR*, Cho YS, Ko YG, Byun Y, Park J. Enhancing immunogenic cell death through caspase-3 amplification with MPD1 and AZD7648 combination therapy., (In preparation)
16. Park SJ*, Kim HR*, Cho YS, Ko YG, Byun Y, Park J. Enhancing immunogenic cell death through caspase-3 amplification with MPD1 and AZD7648 combination therapy., (In preparation)
17. Shrestha S, Jeong JH, Kim HR*, Yook S*, Transforming the tumor microenvironment: CD44-targeted nanoparticles in a 3D spheroidal model of ovarian cancer stem cells and macrophage., (In preparation)
17. Shrestha S, Jeong JH, Kim HR*, Yook S*, Transforming the tumor microenvironment: CD44-targeted nanoparticles in a 3D spheroidal model of ovarian cancer stem cells and macrophage., (In preparation)